Active specific immunotherapy for acute myelogenous leukaemia.
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial / Q000008:administration & dosage; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D001500:BCG Vaccine; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005615:Freezing; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D007962:Leukocytes / Q000276:immunology* / Q000528:radiation effects; D009163:Mycobacterium bovis / Q000276:immunology*; D009368:Neoplasm Transplantation; D011830:Radiation Effects; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin